Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119329) titled 'Real-World Study on the Efficacy and Safety of Zanidatamab in the Treatment of Patients with HER2-Expressing Unresectable Locally Advanced or Metastatic Biliary Tract Cancer' on Feb. 25.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: The First Affiliated Hospital of Xiamen University
Condition:
Unresectable Locally Advanced or Metastatic Biliary Tract Cancer
Intervention:
HER2 1+:None
HER2 2+:None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-03-01
Target Sample Size: HER2 1+:10;HER2 2+:10;HER2 3+:10;
Countries of Recruitment:
China
To ...